Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Date:3/3/2010

Royalty Revenue. We derive additional revenue from royalties paid to us by partners that develop, market and sell products incorporating certain of our proprietary technologies. Currently, the substantial majority of our royalty revenues are derived from sales by Boston Scientific Corporation ("BSC") of TAXUS(R) coronary stent systems incorporating the drug paclitaxel.

Royalty revenue derived from sales of TAXUS stent systems by BSC declined by 8% during the fourth quarter of 2009 as compared to the fourth quarter of 2008 and by 32% during the year ended December 31, 2009 as compared to the year ended December 31, 2008. The decline in royalty revenues during the fourth quarter and year ended December 31, 2009 was a result of lower sales of TAXUS stent systems by BSC, as sales of TAXUS continued to be negatively impacted by competitive pressure in the drug-eluting coronary stent market, most specifically by negative marketing campaigns conducted by BSC's competitors suggesting clinical advantages of their drug-eluting stent products as compared to TAXUS. Royalty revenue for year ended December 31, 2009 was based on BSC's net sales for the period October 1, 2008 to September 30, 2009 of $926 million, of which $411 million was in the United States, compared to net sales of '/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... has sepsis, a life-threatening condition in which bacteria or ... fast for antibiotics to help. A new device inspired ... at Harvard,s Wyss Institute for Biologically Inspired Engineering may ... "Even with the best current treatments, sepsis patients are ... of the time," said Mike Super, Ph.D., Senior Staff ...
(Date:9/15/2014)... September 15, 2014 Bioptigen ... imaging OCT system for the optical device metrology and ... EnvisuTM S4410 SDOCT for Contact Lens Metrology is ... and high complexity contact lens, IOL structures, and donor ... a complete contact lens immersed in a hydration bath ...
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... Market by Product, by Services, by Technology, by Application - ... Whole Exome Sequencing (WES) is next-generation technology used ... the exon. The exome, which is the total of all ... genome and is actually converted into proteins after translation. It ...
(Date:9/15/2014)... Die zweite jährliche International Plasma ... 18. Oktober stattfinden. Die IPAW ist eine gemeinsame ... (PPTA) und ihrer Mitgliedsunternehmen und hat ... für die Gewinnung von Quellplasma zu steigern ... Verbessern von Leben zu würdigen , Das ...
Breaking Biology Technology:Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3
... , , , FORT ... Board: OMCM), a leader in integrated electronic data capture (EDC) ... selected by a leading European based Contract Research Organization (CRO) ... in rheumatoid arthritis (RA). Phase III clinical studies serve to ...
... ANNAPOLIS, Md., Aug. 13 PharmAthene, Inc. (NYSE Amex: ... chemical threats, today reported financial and operational results for the second ... For the second quarter of 2009, PharmAthene recognized revenues ... of 2008. For the six months ended June 30, 2009 ...
... China, Aug. 13 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc., (NYSE ... of,modernized traditional Chinese medicine ("TCM") based in Chengdu, China, ... State Food and Drug,Administration (SFDA) to produce Sanqi Tablets ... and Yinqiao Jiedu Tablets in,dosage form of 0.5 gram/tablet ...
Cached Biology Technology:Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 3PharmAthene Reports Second Quarter 2009 Financial and Operational Results 4PharmAthene Reports Second Quarter 2009 Financial and Operational Results 5PharmAthene Reports Second Quarter 2009 Financial and Operational Results 6PharmAthene Reports Second Quarter 2009 Financial and Operational Results 7PharmAthene Reports Second Quarter 2009 Financial and Operational Results 8Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 3
(Date:9/15/2014)... that reef biodiversity may not provide the level of ... In an international study published today, Professor David Bellwood ... Studies (Coral CoE) says we need to identify and ... In coral reefs, just as in any modern-day society, ... and functioning. , Professor Bellwood says, in many ...
(Date:9/15/2014)... million years after it formed may have been surprisingly ... and active crustal plates. , This alternate view of ... substantial new support from the first detailed comparison of ... ago with those formed contemporaneously in Iceland, which has ... Earth. , The study was conducted by a team ...
(Date:9/15/2014)... who transplanted combinations of wild, domesticated, and ... to new environments found that within 5 ... foreign genes from wild populations that hybridized ... Applications study provides evidence that natural ... that hybridized populations experience as a result ...
Breaking Biology News(10 mins):Specialized species critical for reefs 2Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... Australian scientists have found that the bacterium Cupriavidus ... toxic gold compounds to their metallic form using active ... on gold surfaces but have never clearly elucidated their ... that there may be a biological reason for the ...
... . , Leishmania is a deadly parasitic disease ... million new cases reported every year. Until recently, scientists were unsure ... now been solved according to a new study published in ... a scientist at the Research Institute of the McGill University ...
... Communication Intelligence Corporation ("CIC") (OTC Bulletin Board: ... for business process automation in the financial industry* ... announced today that a top-three U.S. bank will ... rollout including several thousand recently acquired branches. , ...
Cached Biology News:Bacterium helps formation of gold 2Major discovery opens door to leishmania treatment 2Top-Three US Bank Chooses CIC Electronic Signature Technology for Branch-Wide Deployment 2Top-Three US Bank Chooses CIC Electronic Signature Technology for Branch-Wide Deployment 3
...
CREB-2 (H-290)...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Biology Products: